GlassScriptPhysician profile
Susan E Henrikson
NPI 1659312999
$1,625.36
in general payments reported to CMS, 2019-2025
22 companies · $487 in 2025
The $487 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $99.71 · 2021: $215 · 2023: $90.29 · 2024: $375 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $951.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $278.87 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $264.35 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $219.79 | 2023-2024 | Gardasil 9, Vaxelis, Gardasil |
| Kaleo, INC. | $145.55 | 2019-2024 | Auvi-Q |
| Cranial Technologies, INC | $93.16 | 2019-2024 | Doc Band |
| Ironshore Pharmaceuticals INC. | $86.82 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $70.58 | 2021 | |
| Sanofi Pasteur INC. | $61.42 | 2019-2024 | |
| Phadia US INC. | $59.80 | 2019-2024 | Immunocap |
| Takeda Pharmaceuticals U.S.A., INC. | $42.83 | 2019-2021 | |
| Verrica Pharmaceuticals INC. | $37.78 | 2024 | Ycanth |
| Seqirus USA INC | $34.27 | 2021-2025 | Flucelvax |
| Corium, LLC | $33.39 | 2025 | Azstarys |
| Glaxosmithkline, LLC. | $30.54 | 2019 | |
| Adlon Therapeutics L.P. | $27.72 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $26.76 | 2025 | Dyanavel Xr |
| Ultragenyx Pharmaceutical INC. | $22.97 | 2025 | Dojolvi |
| Genentech USA, INC. | $20.46 | 2019 | |
| Shire North American Group INC | $17.92 | 2019 | |
| Genentech, INC. | $17.66 | 2020 | |
| Vertical Pharmaceuticals, LLC | $16.73 | 2024 | Relexxii |
| Sanofi-Aventis U.S. LLC | $15.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Henrikson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.